Interpace Biosciences, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OID
Ampersand 2018 Limited Partnership converted 28,000 shares of Series C Convertible Preferred Stock into 13,861,386 shares of Interpace Biosciences common stock.
OID
Christopher McCarthy, CFO of Interpace Biosciences, reports the vesting of restricted stock units and subsequent withholding of shares to cover tax obligations.
OID
Form 4: Interpace Biosciences Investor 1315 Capital II, L.P. Exchanges Series B Preferred Stock for Series C
1315 Capital II, L.P., a 10% owner of Interpace Biosciences, exchanged its Series B Convertible Preferred Stock for newly created Series C Convertible Preferred Stock on October 11, 2024.
OID
Ampersand 2018 Limited Partnership exchanged its existing shares of Interpace Biosciences Series B Preferred Stock for newly created Series C Convertible Preferred Stock on October 11, 2024.